AR131202A1 - Compuesto heterocíclico y uso del mismo - Google Patents

Compuesto heterocíclico y uso del mismo

Info

Publication number
AR131202A1
AR131202A1 ARP230103223A ARP230103223A AR131202A1 AR 131202 A1 AR131202 A1 AR 131202A1 AR P230103223 A ARP230103223 A AR P230103223A AR P230103223 A ARP230103223 A AR P230103223A AR 131202 A1 AR131202 A1 AR 131202A1
Authority
AR
Argentina
Prior art keywords
heterocyclic compound
receptor agonist
agonist activity
compound
orexin type
Prior art date
Application number
ARP230103223A
Other languages
English (en)
Inventor
Asato Kina
Zenichi Ikeda
Mitsunori Kono
Yuya Oguro
Osamu Kubo
Toru Yamashita
Kazuaki Takami
Takafumi Yukawa
Masaki Seto
Makoto Kamata
Kenjiro Sato
Masataka Murakami
Yusuke Sasaki
Matthew Thomas Reynolds
Minoru Nakamura
Taku Kamei
Hiroyuki Kakei
Fumie Yamaguchi
Tomohiro Ohashi
Takuto Kojima
Keiko Kakegawa
Florian Pnner
Shinji Nakamura
Nao Morishita
Tadashi Hidaka
Sachie Takashima
Takahiko Taniguchi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR131202A1 publication Critical patent/AR131202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto heterocíclico que tiene actividad agonista del receptor de orexina tipo 2. Se proporciona un compuesto de fórmula (1), en donde cada símbolo es como se describe en la memoria descriptiva, o una sal del mismo tiene una actividad agonista del receptor de orexina tipo 2 y es útil como agente para la profilaxis o el tratamiento de la narcolepsia.
ARP230103223A 2022-11-30 2023-11-29 Compuesto heterocíclico y uso del mismo AR131202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263385598P 2022-11-30 2022-11-30

Publications (1)

Publication Number Publication Date
AR131202A1 true AR131202A1 (es) 2025-02-26

Family

ID=89223464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103223A AR131202A1 (es) 2022-11-30 2023-11-29 Compuesto heterocíclico y uso del mismo

Country Status (13)

Country Link
US (1) US20240217957A1 (es)
EP (1) EP4626546A1 (es)
JP (1) JP2025539434A (es)
KR (1) KR20250105712A (es)
CN (1) CN120641412A (es)
AR (1) AR131202A1 (es)
AU (1) AU2023403030A1 (es)
CL (1) CL2025001563A1 (es)
CO (1) CO2025007591A2 (es)
IL (1) IL320814A (es)
MX (1) MX2025006141A (es)
TW (1) TW202440562A (es)
WO (1) WO2024116086A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
LT3984994T (lt) 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11059780B2 (en) 2017-03-08 2021-07-13 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2019027003A1 (ja) 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7339250B2 (ja) 2018-06-29 2023-09-05 武田薬品工業株式会社 複素環化合物およびその用途
WO2020004537A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
US12071434B2 (en) 2018-12-12 2024-08-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7253640B2 (ja) 2019-01-31 2023-04-06 武田薬品工業株式会社 複素環化合物およびその用途
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US12448377B2 (en) 2019-11-27 2025-10-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
KR20250105712A (ko) 2025-07-08
IL320814A (en) 2025-07-01
CO2025007591A2 (es) 2025-06-26
JP2025539434A (ja) 2025-12-05
CN120641412A (zh) 2025-09-12
EP4626546A1 (en) 2025-10-08
TW202440562A (zh) 2024-10-16
WO2024116086A1 (en) 2024-06-06
US20240217957A1 (en) 2024-07-04
AU2023403030A1 (en) 2025-06-05
CL2025001563A1 (es) 2025-09-05
MX2025006141A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
CO2021011188A2 (es) Compuesto heterocíclico y su uso
CO2020001879A2 (es) Compuesto heterocíclico y su uso
UY37103A (es) Compuestos de piperidina sustituido y su uso
CL2025001563A1 (es) Compuesto heterocíclico y uso del mismo
MX2022016212A (es) Profármacos de tripamina.
CO2025005865A2 (es) Compuesto heterocíclico
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
MX2023000693A (es) Inhibidor de egfr.
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
MX2020005909A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo.
CO2022000481A2 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
UY31781A (es) Derivados de iminopiridina y su uso
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
PE20181522A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR070874A1 (es) Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
CO2025012357A2 (es) Compuestos heterocíclicos macrocíclicos y sus usos
MX2022011475A (es) Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus.
UY38472A (es) Moduladores de la expresión de foxp3
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CL2025003547A1 (es) Antagonista del receptor de tipo 2 de melanocortina
MX2019001696A (es) Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.